Jordi Martínez-Quintanilla

Jordi Martínez-Quintanilla

Auto-generated profile, based on publicly available information

Jordi Martínez-Quintanilla

Stem Cells and Cancer Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2010 in Cancer Gene Therapy
Verified
Journal Article
Closed access
JGJavier García-Castro
Javier García-Castro
RAR Alemany
R Alemany
MCM Cascalló
M Cascalló
JMJ Martínez-Quintanilla
J Martínez-Quintanilla
MAM del Mar Arriero
M del Mar Arriero
MRManuel Ramírez
Manuel Ramírez

16 May 2014 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
MDMatthias Duebgen
Matthias Duebgen
JMJordi Martinez-Quintanilla
Jordi Martinez-Quintanilla
KTKaoru Tamura
Kaoru Tamura
SHShawn Hingtgen
Shawn Hingtgen
NRNavid Redjal
Navid Redjal
KSKhalid Shah
Khalid Shah
The current treatment regimen for malignant glioblastoma multiforme (GBM) is tumor resection followed by chemotherapy and radiation therapy. Despite the proven safety of oncolytic herpes simplex virus (oHSV) in clinical trials for GBMs, its efficacy is suboptimal mainly because of insufficient viral spread after tumor resection. Human mesenchymal stem cells (MSC) were loaded with oHSV (MSC-oHSV), and their fate was explored by real-time imaging in vitro and in vivo. Using novel diagnostic and armed oHSV mutants and real-time multimodality imaging, the efficacy of MSC-oHSV and its proapoptotic variant, oHSV-TRAIL encapsulated in biocompatible synthetic extracellular matrix (sECM), was tested in different mouse GBM models, which more accurately reflect the current clinical settings of malignant, resistant, and resected tumors. All statistical tests were two-sided. MSC-oHSVs effectively produce oHSV progeny, which results in killing of GBMs in vitro and in vivo mediated by a dynamic process of oHSV infection and tumor destruction. sECM-encapsulated MSC-oHSVs result in statistically significant increased anti-GBM efficacy compared with direct injection of purified oHSV in a preclinical model of GBM resection, resulting in prolonged median survival in mice (P < .001 with Gehan–Breslow–Wilcoxin test). To supersede resistant tumors, MSC loaded with oHSV-TRAIL effectively induce apoptosis-mediated killing and prolonged median survival in mice bearing oHSV- and TRAIL-resistant GBM in vitro (P < .001 with χ2 contingency test). Human MSC loaded with different oHSV variants provide a platform to translate oncolytic virus therapies to clinics in a broad spectrum of GBMs after resection and could also have direct implications in different cancer types.

1 January 2015 in Molecular Therapy
Verified
Journal Article
Open access
JMJordi Martinez-Quintanilla
Jordi Martinez-Quintanilla
DHDerek He
Derek He
Hiroaki WakimotoHiroaki Wakimoto
Hiroaki Wakimoto
RARamon Alemany
Ramon Alemany
KSKhalid Shah
Khalid Shah
Despite the proven safety of oncolytic viruses (OV) in clinical trials for glioblastoma multiforme (GBM), their efficacy has been hindered by sub-optimal spreading within the tumor. We show that hyaluronan (HA), an important component of extracellular matrix (ECM), is highly expressed in a majority of tumor xenografts established from patient-derived GBM lines that present both invasive and nodular phenotypes. Intratumoral injection of a conditionally replicating adenovirus expressing soluble hyaluronidase (ICOVIR17) into nodular-GBM, mediated HA degradation and enhanced viral spread, resulting in a significant antitumor effect and mice survival. In an effort to translate OV based therapeutics into clinical settings, we encapsulated human adipose-derived mesenchymal stem cells (MSC) loaded with ICOVIR17 in biocompatible synthetic ECM (sECM) and tested their efficacy in a clinically relevant mouse model of GBM resection. Compared with direct injection of ICOVIR17, sECM-MSC loaded with ICOVIR17 resulted in a significant decrease in tumor re-growth and increased mice survival. This is the first report of its kind revealing the expression of HA in GBM and the role of OV mediated HA targeting in clinically relevant mouse model of GBM resection and thus has clinical implications.

6 August 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
IPIsabel Puig
Isabel Puig
STStephan P. Tenbaum
Stephan P. Tenbaum
ICIrene Chicote
Irene Chicote
OAOriol Arqués
Oriol Arqués
JMJordi Martínez-Quintanilla
Jordi Martínez-Quintanilla
HPHéctor G. Palmer
Héctor G. Palmer
Dormant or slow-cycling tumor cells can form a residual chemoresistant reservoir responsible for relapse in patients, years after curative surgery and adjuvant therapy. We have adapted the pulse-chase expression of H2BeGFP for labeling and isolating slow-cycling cancer cells (SCCCs). SCCCs showed cancer initiation potential and enhanced chemoresistance. Cells at this slow-cycling status presented a distinctive nongenetic and cell-autonomous gene expression profile shared across different tumor types. We identified TET2 epigenetic enzyme as a key factor controlling SCCC numbers, survival, and tumor recurrence. 5-Hydroxymethylcytosine (5hmC), generated by TET2 enzymatic activity, labeled the SCCC genome in carcinomas and was a predictive biomarker of relapse and survival in cancer patients. We have shown the enhanced chemoresistance of SCCCs and revealed 5hmC as a biomarker for their clinical identification and TET2 as a potential drug target for SCCC elimination that could extend patients’ survival.

6 February 2013 in Stem Cells
Verified
Journal Article
Open access
PDF file
JMJordi Martinez-Quintanilla
Jordi Martinez-Quintanilla
DBDeepak Bhere
Deepak Bhere
PHPedram Heidari
Pedram Heidari
DHDerek He
Derek He
UMUmar Mahmood
Umar Mahmood
KSKhalid Shah
Khalid Shah
Therapeutically engineered stem cells (SC) are emerging as an effective tumor‐targeted approach for different cancer types. However, the assessment of the long‐term fate of therapeutic SC post‐tumor treatment is critical if such promising therapies are to be translated into clinical practice. In this study, we have developed an efficient SC‐based therapeutic strategy that simultaneously allows killing of tumor cells and assessment and eradication of SC after treatment of highly malignant glioblastoma multiforme (GBM). Mesenchymal stem cells (MSC) engineered to co‐express the prodrug converting enzyme, herpes simplex virus thymidine kinase (HSV‐TK) and a potent and secretable variant of tumor necrosis factor apoptosis‐inducing ligand (S‐TRAIL) induced caspase‐mediated GBM cell death and showed selective MSC sensitization to the prodrug ganciclovir (GCV). A significant decrease in tumor growth and a subsequent increase in survival were observed when mice bearing highly aggressive GBM were treated with MSC coexpressing S‐TRAIL and HSV‐TK. Furthermore, the systemic administration of GCV post‐tumor treatment selectively eliminated therapeutic MSC expressing HSV‐TK in vitro and in vivo, which was monitored in real time by positron emission‐computed tomography imaging using 18F‐FHBG, a substrate for HSV‐TK. These findings demonstrate the development and validation of a novel therapeutic strategy that has implications in translating SC‐based therapies in cancer patients. STEM Cells 2013;31:1706–1714

1 November 2010 in Molecular Therapy
Verified
Journal Article
Open access
JRJuan Jose Rojas
Juan Jose Rojas
SGSonia Guedan
Sonia Guedan
PSPeter F Searle
Peter F Searle
JMJordi Martinez-Quintanilla
Jordi Martinez-Quintanilla
RGRaúl Gil-Hoyos
Raúl Gil-Hoyos
RARamon Alemany
Ramon Alemany
Oncolytic adenoviruses are promising anticancer agents due to their ability to self-amplify at the tumor mass. However, tumor stroma imposes barriers difficult to overcome by these agents. Transgene expression is a valuable strategy to counteract these limitations and to enhance antitumor activity. For this purpose, the genetic backbone in which the transgene is inserted should be optimized to render transgene expression compatible with the adenovirus replication cycle and to keep genome size within the encapsidation size limit. In order to design a potent and selective oncolytic adenovirus that keeps intact all the viral functions with minimal increase in genome size, we inserted palindromic E2F-binding sites into the endogenous E1A promoter. The insertion of these sites controlling E1A-Δ24 results in a low systemic toxicity profile in mice. Importantly, the E2F-binding sites also increased the cytotoxicity and the systemic antitumor activity relative to wild-type adenovirus in all cancer models tested. The low toxicity and the increased potency results in improved antitumor efficacy after systemic injection and increased survival of mice carrying tumors. Furthermore, the constrained genome size of this backbone allows an efficient and potent expression of transgenes, indicating that this virus holds promise for overcoming the limitations of oncolytic adenoviral therapy.